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Abstract

Literature Review

Discussion

Applicability to Clinical Practice

In this study, a low carbohydrate diet and metformin pharmacotherapy were compared
to determine their effect on HbA1c in the type two diabetic patient. Several high quality
studies were examined along with each treatments effect on mainly HbA1c, but also
other parameters such as body weight, cholesterol, and fasting and post prandial blood
glucose levels. The study showed that both the low carbohydrate diet and metformin
pharmacotherapy were effective at lowering HbA1c in the type two diabetic patient.
The low carbohydrate diet showed a 0.2% increase in HbA1c all the way to a 2.2%
decrease in baseline HbA1c in the studies that were examined. The metformin
pharmacotherapy showed between a 0.45% decrease up to a greater than 1% decrease
from baseline HbA1c in the studies examined within this project. After looking at the
other parameters that were affected by each treatment, it was concluded that
choosing treatment between the two options studied will be highly dependent on each
individual patient and their readiness and willingness to implement lifestyle changes.
Both methods of treatment are equally as effective and can be beneficial to different
patients.

•Advantages of using diet management as first line treatment of type two diabetes
mellitus. The study done by Kirk et al. (2008) showed that the low carbohydrate diet
groups decreased their HbA1c significantly with an average of 0.79%. The original
research study done by Yamada et al. (2014) also showed a decrease in HbA1c of 0.6% in
the patients that were studied. A meta-analysis done by Huntriss et al. (2017) examined
eighteen studies and at the end of the twelve of the seventeen studies that were
completed showed a decrease in HbA1c of more than 0.2% and of these studies, four of
them had a decrease of more than 0.5%. There was a study done by Ajala et al. (2013)
that determined that the low carbohydrate, low GI, Mediterranean, and high protein
diets all reduced HbA1c by between 0.12% and 0.5% compared to the control diets within
each group. A critical review of carbohydrate restriction on diabetes management that
was done by Feinman et al. (2015) showed that a low carbohydrate diet decreased
HbA1c by an average of 0.68%. This study was particularly interesting because the low
carbohydrate diet was done as a first line treatment for managing diabetes. The study
done by Tay et al. (2015) showed that the HbA1c was decreased the same amount in
both the low carbohydrate and high carbohydrate diet groups that were being studied.
Kodama et al. (2009) compared a high carbohydrate low fat diet with a low
carbohydrate high fat diet. The analysis showed that there was no significant
difference in the HbA1c outcomes. Jung and Choi (2017) showed there was no
difference in HbA1c between the low carbohydrate and high carbohydrate diet groups.
•Disadvantages of using diet management as first line treatment of type two
diabetes mellitus. The most prominent disadvantage of using a low carbohydrate diet
as first line treatment for T2DM is adherence. One thing that Feinman et al. (2015)
noted was that the low carbohydrate diet group had unlimited access to food, but they
had to restrict their carbohydrate intake which they thought was easier to adhere to
than other types of diets that had a strict reduction in calories leading to a lower
adherence rate. Although many of these studies showed that the low carbohydrate
diet was beneficial for several health parameters, Kirk et al. (2008) discussed their
concern about the sustainability of the results achieved by the low carbohydrate diet
once the patient goes back to a higher carbohydrate intake. Another disadvantage of
using a low carbohydrate diet as a first line treatment of T2DM is that, as stated above
in several studies, the low carbohydrate diet is not improving diabetic parameters
significantly more than any other type of diet. The important thing seems to be a
reduction in the patient’s weight which can be obtained by any type of diet that causes
a person to decrease their weight.
•Advantages of using metformin as first line treatment of type two diabetes mellitus.
The study done by Gonzalez-Ortiz et al. (2012) showed a greater than one percent drop
in HbA1c in more than 60% of the participants at the completion of the study. Kashi,
Mahrooz, Kianmehr, and Alizadeh (2016) found that over a three-month period, the
patients undergoing metformin therapy had a 0.65% decrease in HbA1c. The study done
by Nichols et al. (2016) was broken down into adherence groups. Adherence below 50%
showed no statistical difference in HbA1c, adherence between 50% and 79% had an
average decrease of 0.45% in HbA1c, and the adherence group of 80% or greater was
associated with a decrease of 0.73% in their HbA1c. Romanelli et al. (2015) studied two
groups that initiated metformin therapy at different times. During this study, the
researchers found that the early initiation group had a 0.36% greater decrease in HbA1c
and were also more likely to reach a HbA1c target value of less than 7%. Williams et al.
(2014) found that the patients that were on the maximum dose of metformin had a
0.61% greater decrease in their HbA1c compared to the untreated group.
•Disadvantages of using metformin as first line treatment of type two diabetes
mellitus. The disadvantages of using metformin include, but are not limited to, possible
hypoglycemic events, lactic acidosis, cost, and also the risk of not making any lifestyle
changes to reverse the disease itself. Since metformin prevents the formation of
glucose, this can decrease the amount of glucose in the bloodstream and cause
hypoglycemia. (DynaMed Plus, 2017e) This can also be caused by a patient missing or
skipping a meal, excessively exercising, or drinking alcohol. This risk is increased if the
patient moves from solo metformin pharmacotherapy to combination therapy using
metformin and another antihyperglycemic drug. According to Buse et al. (2016) the
accumulation of metformin can lead to lactic acidosis. The use of metformin in a patient
with other comorbidities such as heart failure, renal insufficiency, hypoxia, or sepsis can
increase the risk of lactic acidosis (DynaMed Plus, 2017e). With the amount of people
diagnosed with T2DM, there is potentially 54 billion dollars being spent on metformin
alone every year making it a financial burden on those involved. The final disadvantage
of using metformin as initial therapy for T2DM is not actually treating the underlying
cause of the T2DM. As described by Roumie et al. (2016), once patients are put on
metformin pharmacotherapy without initiating lifestyle changes (such as dietary
management, physical activity, or diabetic education), these patients have a 50%
chance of intensifying their pharmacotherapy to combination therapy within four
years.

In newly diagnosed type two diabetics presenting for initial treatment, does a low
carbohydrate diet or metformin have a greater effect on lowering HbA1c?
• Through the above research, it was found that using a low carbohydrate diet almost
always decreased the patient’s HbA1c.
• There was between a 0.2% decrease (Huntriss et al., 2017) and a 2.2% decrease (Kirk
et al., 2008) in HbA1c.
• Metformin showed a 0.45% decrease in HbA1c (Nichols et al., 2016) up to a greater
than one percent decrease in HbA1c as expressed by Gonzalez-Ortiz et al. (2012).
• A problem that was encountered with this research was that the amount of studies
within the past ten years were limited.
What are the advantages of a low carbohydrate on lowering HbA1c?
• Provides additional improvement in health parameters including weight, high
density lipoprotein cholesterol, triglycerides, and HbA1c.
• Many of the studies showed no significant difference between the HbA1c effects
from the low carbohydrate diet versus the other types of diets studied. Ajala et al.
(2013) Tay et al. (2015), Kodoma et al. (2009), and Jung and Choi (2017)
What are the disadvantages of a low carbohydrate diet on lowering HbA1c?
• Many of the studies did not specify what they meant by low carbohydrate. Because
of this, it is not clear that the patients were consuming the same amount of
carbohydrates in all of the studies.
• The final disadvantage is adherence. Not every patient is going to be willing to
adhere to a low carbohydrate diet in order to lower their HbA1c.
What are the advantages of metformin pharmacotherapy on lowering HbA1c?
• The studies show that a patient taking metformin has a decrease in HbA1c ranging
from 0.45% to greater than 1% (Nichols et al., 2016; Gonzalez-Ortiz et al. 2012).
• Romanelli et al. (2015) found that patients that started taking metformin within
approximately three weeks of their diagnosis had a significantly higher chance of
reaching the goal range of less than 7% in HbA1c. This group also had a 0.36% greater
decrease in HbA1c during the study.
• Nichols et al. (2016) found that in the group that had a lower than 50% adherence to
their prescribed treatment, there was no change in HbA1c. The group that had
between 50% and 79% adherence saw a decrease in HbA1c of approximately 0.45%
and the group with 80% or greater adherence to their metformin therapy saw a
decrease of about 0.73% in their HbA1c.
What are the disadvantages of metformin pharmacotherapy on lowering HbA1c?
• The main two serious side effects that should be watched for with metformin are
hypoglycemia and lactic acidosis (Bardal et al., 2011; Buse et al., 2016).
• The cost of metformin can be a huge expense which could be up to 54 billion dollars
per year being spent on T2DM metformin pharmacotherapy in the United States
alone (Epocrates, 2012).
• Finally, Qaseem et al. (2017) found that most diabetic drugs were shown to lower
HbA1c to approximately the same level. This means that there are different
pharmacotherapy options available that can decrease HbA1c and possibly improve
other health parameters as well.

•Almost one tenth of the population of the United States of America is currently
diagnosed with T2DM according to the American Diabetes Association (2017).
Throughout the research done for this project, it has become evident that there is
more than one way to treat T2DM. The two treatments that have been compared in
depth are metformin pharmacotherapy and a low carbohydrate diet.
•With a low carbohydrate diet, a patient is able to lower their body weight and BMI,
raise their high density lipoprotein cholesterol, lower their triglycerides, and decrease
their HbA1c. The problem is that not every patient is going to be ready and willing to
adhere to a strict diet to treat their type two diabetes. This is where education comes
in. It is important to educate these patients and even involve the registered dietician
and diabetic educator. The low carbohydrate diet is effective at treating T2DM only in
the patients who are ready and willing to adhere to the diet and make a lifestyle
change to improve their health.
•Metformin, on the other hand, has been used as a first line treatment for T2DM for
centuries (Bardal et al., 2011). It has been proven to be effective and is an oral drug that
is not difficult to add into a person’s every day routine. It is believed that even if a
patient begins metformin pharmacotherapy immediately at diagnosis of T2DM, there
must be consultation with a diabetic educator and registered dietician with frequent
follow ups.
•It was not found that either the low carbohydrate diet or metformin
pharmacotherapy was more effective. They were both proven to be effective at
lowering a patient’s HbA1c, but the main thing that was found was that each patient is
different and a treatment that fits well in one patient’s life may not be reasonable in
another patient’s life. Each patient that is diagnosed with T2DM must be educated on
the treatment options and provided the support they need to both decide on a
treatment option and adhere to it.

Introduction
The following research is comparing the effectiveness of a low carbohydrate diet and
metformin on reducing a type two diabetic’s HbA1c (HbA1c). Initial treatments for
T2DM can include, but are not limited to, lifestyle changes and/or metformin. A patient
that wishes to use lifestyle interventions will likely use a mix of dietary changes
facilitated by a registered dietitian (Grade A recommendation), increased physical
activity to improve high density lipoprotein cholesterol levels (Grade B
recommendation), and education from a diabetic educator (Grade B recommendation)
(DynaMed Plus, 2017a). Metformin is a drug that is often used as initial pharmacologic
therapy (Grade A recommendation) for T2DM (DynaMed Plus, 2017e). Metformin
lowers basal and postprandial blood glucose levels by decreasing the production of
glucose in the liver and decreasing intestinal absorption of glucose in the distal small
intestine as described by DynaMed Plus (2017e).

Statement of the Problem
The number of T2DM patients continues to rise each year. Medical providers face the
challenge of treating type two diabetes on a daily basis and there are numerous
possibilities available as treatment options. Medical providers and patients need to be
able to choose their first line treatment based on scientific evidence, effectiveness, and
how that treatment will fit in with the patient’s personal lifestyle. The low
carbohydrate diet and metformin need to be compared in terms of effectiveness on
HbA1c as the solo first line treatment of diabetes mellitus.

Research Questions
• In newly diagnosed type two diabetics presenting for initial treatment, does a low
carbohydrate diet or metformin have a greater effect on lowering glycosylated
hemoglobin?
• What are the advantages of a low carbohydrate diet on lowering glycosylated
hemoglobin?
• What are the disadvantages of a low carbohydrate diet on lowering glycosylated
hemoglobin?
• What are the advantages of metformin pharmacotherapy on lowering glycosylated
hemoglobin?
• What are the disadvantages of metformin pharmacotherapy on lowering
glycosylated hemoglobin?
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